Drug plus radiation for HER2-negative breast cancer brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial is testing a combination of a targeted drug (Sacituzumab Govitecan) and radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can help shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-negative breast cancer
- You have at least one brain tumor that can be seen on an MRI
- You are 18 years or older
- You have not had a bad reaction to a similar drug called Sacituzumab Govitecan before
- You are not pregnant, nursing, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests a combination of a targeted antibody-drug (sacituzumab govitecan) and chemotherapy given into the spinal fluid. It is for people with HER2-negative breast cancer that has spread to the membranes around the brain and spinal cord (leptomeningeal metastases). The goal is to see if this treatment can help control the cancer in the central nervous system.
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Hear when a new Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.